Wound management is a vital and evolving discipline within healthcare, addressing both acute and chronic wounds with advanced technologies, specialized treatments, and multidisciplinary care. With over 60 million people affected globally each year, the demand for effective, patient-friendly, and sustainable solutions has never been more urgent. Visionaries in this field are reshaping outcomes for patients while easing the strain on healthcare systems—and Bert J. Quint is at the forefront of this movement.
As the Founder and CEO of DEBx Medical, Quint leads a company known for its disruptive innovation in wound care. His journey from biochemist to healthcare entrepreneur is grounded in a mission to deliver life-changing outcomes and reduce the burden of chronic wounds. Through pioneering approaches that eliminate infections without antibiotics and drive sustainable healing, Quint and his team are transforming how the world heals.
A Mission Born from Collaboration and Passion
Quint’s venture into wound care began with a shared vision alongside Professor Carlo Bignozzi and Dr. Alberto Cogo. Together, they developed a novel method capable of disrupting deep-tissue biofilms—a breakthrough that changed non-healing wounds into granulating, epithelizing wounds after a single treatment. Quint recalls, “Our method worked and transformed wounds that had not responded to any therapy.” Backed by continuous support from his wife Petra, this innovation laid the foundation for DEBx Medical.
Motivated by the immense cost and suffering caused by chronic wounds, Quint focused on addressing root causes without relying on antibiotics—thereby avoiding complications like resistance. He believes healthcare must shift “from procedures to outcomes and from cost to value,” and this philosophy fuels DEBx Medical’s approach to delivering both effectiveness and affordability.
Disruptive Innovation in Action
DEBx Medical’s core innovation is a treatment that eliminates infections in non-healing wounds—without the need for antibiotics in over 94% of cases. It acts broadly against all bacterial and yeast strains, including MRSA, and typically requires only one application. This has changed lives, as seen in the case of a 93-year-old woman in Spain whose 16-year venous ulcer healed completely within two months of treatment.
Rather than competing with existing therapies, DEBx complements them. Whether it’s skin grafts or negative pressure wound therapy (NPWT), their method enhances the efficacy of other products. “We are not a competitor; we are complementary,” says Quint—positioning DEBx as a vital collaborator in the global wound care ecosystem.
Technology-Driven, Patient-Centered
Chronic wounds are not just a clinical challenge—they’re an economic one. In the U.S. alone, the cost rivals the five most expensive cancer treatments combined. DEBx Medical addresses this through high-impact, cost-effective solutions powered by emerging technologies.
Artificial intelligence and real-time tissue analytics are central to their strategy. Collaborating with Swiss-based IMITO, they’re developing AI-driven tools to support clinical decision-making and optimize treatment timelines. “AI will allow faster, more efficient wound healing,” says Quint, signaling a data-informed future for wound care.
Leading with Vision, Empowering Talent
Quint’s leadership is rooted in collaboration and creativity. Drawing from his experience with major U.S. companies, he brings together diverse, dynamic minds to solve complex healthcare challenges. “I surround myself with young, smart, driven people,” he shares, fostering a culture where ideas flourish and innovation thrives.
This leadership ethos extends to talent development. Many of DEBx Medical’s first employees have grown into leaders in their own right—a testament to Quint’s belief in giving individuals the space and mentorship to succeed. He credits his long-time partners Bignozzi and Cogo for cultivating an environment of open reflection and learning, driving constant improvement.
Building for the Future
Quint has bold ambitions: to fundamentally reshape global wound care. With rising diabetes rates and an aging population, chronic wounds are set to become even more prevalent. “Twenty-five percent of diabetic patients will develop chronic wounds, and a quarter of those risk losing a limb,” he warns. The company is accelerating development on new solutions, including reinfection prevention tools, wound fillers, and an over-the-counter version of their current therapy.
Their impact, however, goes beyond medicine. Sustainability is a core pillar of DEBx Medical’s operations. Their main product is fully biodegradable—“a happy accident,” as Quint describes it. The company is also investing in greener manufacturing and supply chain practices, as well as energy-efficient R&D methods, reinforcing their commitment to both environmental and human health.
Rooted in Purpose, Driven by Results
For Quint, the mission is personal. Witnessing a patient’s nine-month-old wound begin healing within 48 hours of treatment changed everything. “That was the moment I knew I had to dedicate myself fully to this,” he says. His advice to aspiring healthcare innovators? “Focus on solutions that truly make a difference. Grow a thick skin. Choose the right people and partners. And never lose sight of the patient.”
That patient-centered approach defines DEBx Medical. Their treatments are not just clinically sound—they’re intuitive, accessible, and designed for real-world use. By listening to patients and caregivers, the company refines its offerings to ensure every product delivers tangible improvements in quality of life.
Shaping the Standard of Care
Under Bert J. Quint’s leadership, DEBx Medical is more than a company—it’s a movement to revolutionize wound care. With a steadfast commitment to innovation, sustainability, and patient well-being, Quint is changing how the world heals—one breakthrough at a time.
